149 related articles for article (PubMed ID: 28648785)
1. LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients.
Iwamoto N; Shimomura A; Tamura K; Hamada A; Shimada T
J Pharm Biomed Anal; 2017 Oct; 145():33-39. PubMed ID: 28648785
[TBL] [Abstract][Full Text] [Related]
2. Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis.
Iwamoto N; Shimada T; Terakado H; Hamada A
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1023-1024():9-16. PubMed ID: 27155936
[TBL] [Abstract][Full Text] [Related]
3. Application of nano-surface and molecular-orientation limited proteolysis to LC-MS bioanalysis of cetuximab.
Iwamoto N; Takanashi M; Umino Y; Aoki C; Hamada A; Shimada T
Bioanalysis; 2016 May; 8(10):1009-20. PubMed ID: 26972866
[TBL] [Abstract][Full Text] [Related]
4. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis.
Iwamoto N; Hamada A; Shimada T
Anal Biochem; 2018 Jan; 540-541():30-37. PubMed ID: 29128290
[TBL] [Abstract][Full Text] [Related]
5. Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nano-surface and Molecular-Orientation Limited (nSMOL) Proteolysis.
Iwamoto N; Takanashi M; Hamada A; Shimada T
Biol Pharm Bull; 2016 Jul; 39(7):1187-94. PubMed ID: 27150271
[TBL] [Abstract][Full Text] [Related]
6. Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.
Iwamoto N; Takanashi M; Yokoyama K; Yonezawa A; Denda M; Hashimoto M; Tanaka M; Ito H; Matsuura M; Yamamoto S; Honzawa Y; Matsubara K; Shimada T
J Immunol Methods; 2019 Sep; 472():44-54. PubMed ID: 31201793
[TBL] [Abstract][Full Text] [Related]
7. Implementation of Systematic Bioanalysis of Antibody-Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats.
Jeon EJ; Han JH; Seo Y; Koh EM; Han KH; Hwang K; Jung KJ
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986616
[TBL] [Abstract][Full Text] [Related]
8. Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Pharmacol Res Perspect; 2018 Jul; 6(4):e00422. PubMed ID: 30062014
[TBL] [Abstract][Full Text] [Related]
9. Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab.
Iwamoto N; Yonezawa A; Matsubara K; Shimada T
J Pharm Biomed Anal; 2019 Feb; 164():467-474. PubMed ID: 30447535
[TBL] [Abstract][Full Text] [Related]
10. Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis.
Iwamoto N; Umino Y; Aoki C; Yamane N; Hamada A; Shimada T
Drug Metab Pharmacokinet; 2016 Feb; 31(1):46-50. PubMed ID: 26830079
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1).
Liu Y; Zhou F; Sang H; Ye H; Chen Q; Yao L; Ni P; Wang G; Zhang J
J Pharm Biomed Anal; 2017 Apr; 137():170-177. PubMed ID: 28131055
[TBL] [Abstract][Full Text] [Related]
12. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334
[TBL] [Abstract][Full Text] [Related]
13. Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach.
Iwamoto N; Shimada T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):19-24. PubMed ID: 30392772
[TBL] [Abstract][Full Text] [Related]
14. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
15. LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma.
Jin W; Burton L; Moore I
Bioanalysis; 2018 Jun; 10(11):851-862. PubMed ID: 29863890
[TBL] [Abstract][Full Text] [Related]
16. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab emtansine in breast cancer.
Dirix LY; Rutten A; Huget P; Dirix M
Expert Opin Biol Ther; 2013 Apr; 13(4):607-14. PubMed ID: 23477731
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
Haddley K
Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
[TBL] [Abstract][Full Text] [Related]
19. Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol.
Mohamed HE; Mohamed AA; Al-Ghobashy MA; Fathalla FA; Abbas SS
J Pharm Biomed Anal; 2018 Feb; 150():268-277. PubMed ID: 29258046
[TBL] [Abstract][Full Text] [Related]
20. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR
J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
